Biodesix (BDSX) Gross Margin (2019 - 2026)

Biodesix has reported Gross Margin for 8 years, with the latest figure at 83.55% in Q1 2026.

• For the quarter ending Q1 2026, Gross Margin rose 417.0% year-over-year to 83.55%; the trailing twelve-month figure through Mar 2026 stood at 85.12% (down 400.0% YoY), and the FY2025 full-year result was 91.46%, up 207.0% from the prior year.
• Gross Margin for Q1 2026 stood at 83.55%, down from 93.18% in the prior quarter.
• The five-year high for Gross Margin was 117.9% in Q4 2024, with the low at 50.6% in Q1 2022.
• Historically, Gross Margin has averaged 77.28% across 5 years, with a median of 77.0% in 2023.
• Annual changes were most pronounced in 2024 — Gross Margin soared 4090 bps — and 2025, when it plunged 2472 bps.
• Biodesix's Gross Margin stood at 65.59% in 2022, then rose by 17 bps to 77.0% in 2023, then jumped by 53 bps to 117.9% in 2024, then retreated by 21 bps to 93.18% in 2025, then decreased by 10 bps to 83.55% in 2026.
• The last three Gross Margin figures came in at 83.55% (Q1 2026), 93.18% (Q4 2025), and 81.14% (Q3 2025), per Business Quant data.